

DISCLAIMER

The information presented today is based on CDC's recent guidance and MAY change.

December 29, 2020

Welcome

December 29, 2020

Imelda Garcia, MPH

Associate Commissioner | Laboratory & Infectious Disease Services Division

Discussion Topics

- Population
- Diverse Provider Settings
- Long-term Care
- Local Partnership and Communications
- Second Dose Allocation
- News from the Field
- Manufacturer Education Series
- Resources

Phases and Timeframe of COVID-19 Vaccine Distribution

Draft – for planning purposes only and subject to change

Administration of COVID-19 vaccine will require a phased approach



8/26/20

COVID-19 Critical Population

Phase 1A Healthcare Workers Definition – First Tier

- Paid and unpaid workers in hospital settings working directly with patients who are positive or at high risk for COVID-19. Such as but not limited to:
  - Physicians, nurses, respiratory therapists and other support staff (custodial staff, etc.)
  - Additional clinical staff providing supporting laboratory, pharmacy, diagnostic and/or rehabilitation services
  - Others having direct contact with patients or infectious materials
- Long-term care staff working directly with vulnerable residents. Includes:
  - Direct care providers at nursing homes, assisted living facilities, and state supported living centers
  - Physicians, nurses, personal care assistants, custodial, food service staff
- EMS providers who engage in 9-1-1 emergency services like pre-hospital care and transport
- Home health care workers, including hospice care, who directly interface with vulnerable and high-risk patients
- Residents of long-term care facilities

COVID-19 Critical Population

Phase 1A Healthcare Workers Definition – Second Tier

- Staff in outpatient care settings who interact with symptomatic patients. Such as but not limited to:
  - Physicians, nurses, respiratory therapists and other support staff (custodial staff, etc.).
  - Clinical staff providing diagnostic, laboratory, and/or rehabilitation services
  - Non 9-1-1 transportation for routine care
  - Healthcare workers in corrections and detention facilities
- Direct care staff in freestanding emergency medical care facilities and urgent care clinics.
- Community pharmacy staff who may provide direct services to clients, including vaccination or testing for individuals who may have COVID.
- Public health and emergency response staff directly involved in administration of COVID testing and vaccinations.
- Last responders who provide mortuary or death services to decedents with COVID-19. Includes:
  - Embalmers and funeral home workers who have direct contact with decedents
  - Medical examiners and other medical certifiers who have direct contact with decedents.
- School nurses who provide health care to students and teachers.

COVID-19 Critical Population
Phase 1B Definition

- DSHS will work with vaccine providers and local partners to ensure that people who are 65 and older or have the medical conditions listed below and who also work in front-line and critical industries have access to the vaccine so they will be protected from COVID-19 while on the job.
- Texas equally will strive to ensure vaccine reaches communities with health disparities in accordance with Texas Vaccine Allocation Guiding Principles.

COVID-19 Critical Population
Phase 1B Definition

Texas Phase 1B Vaccine Priorities

- People 65 years of age and older
- People 16 years of age and older with at least one chronic medical condition that puts them at increased risk for severe illness from the virus that causes COVID-19, such as but not limited to:
  - Cancer
  - Chronic kidney disease
  - COPD (chronic obstructive pulmonary disease)
  - Heart conditions, such as heart failure, coronary artery disease or cardiomyopathies
  - Solid organ transplantation
  - Obesity and severe obesity (body mass index of 30 kg/m^2 or higher)
  - Pregnancy
  - Sickle cell disease
  - Type 2 diabetes mellitus

Long-term Care Planning

- The start of the Federal LTCF program will be on December 28th, 2020 with major pharmacy chains.
- Work continues to identify the gap of LTC facilities that did not enroll in the federal program and may need state assistance. Likely this work would begin mid-January 2021

Allocation Key Items

- Organizations must be completely approved.
- Number of healthcare workers is used to guide allocations for this Phase 1A.
- Doses administered is being considered for sites already receiving vaccine.

Local Partnership and Communications

- LHEs should know the locations that received allocations and know circumstances that they are using the vaccine (ID needed, hours, possible local engagement). With this knowledge drive healthcare workers without employer vaccinations to the variety of provider sites.
- LHEs should use the tableau dashboard for visibility on all provider allocations and usage in their jurisdictions.
- Engage local leaders and community gatekeepers to assist in messaging and driving healthcare workers to these locations.
- Encourage all providers to report daily to ImmTrac2.

Summary | Vaccine Distribution | Vaccine Doses Administered | People Vaccinated | About the Data

COVID-19 Vaccination in Texas

DSHS is partnering with vaccine providers across the state to ensure vaccine will be accessible to all Texans at no cost.

Dashboard updated around 4 p.m. each day with data as of 11:59 the previous night.

See the About the Data tab for more information on data sources.

TEXAS Health and Human Services | Texas Department of State Health Services

Vaccination of frontline and vulnerable populations

COVID-19 vaccination is currently available only to frontline and vulnerable populations due to limited supply. Texas will move through several phases to ensure those who need the vaccine most receive it first. We need every Texan's help to make this a success.

Choose population groups from the list below to see them by county in the red boxes by county.

Population Group - Phase 1A

- [x] (All)
- [x] Healthcare - Tier 1 (such as hospitals and EMS)
- [x] Healthcare - Tier 2 (such as medical offices)
- [x] Long-term Care - Assisted Living Residents/Other
- [x] Long-term Care - Nursing Home Residents

Visit the DSHS COVID-19 Vaccine Information page for more details on phases and tiers, and other vaccine info:
https://www.dshs.texas.gov/coronavirus/immunize/vaccine.aspx

Population Groups by County



Texans Vaccinated for COVID-19



People Vaccinated with at least One Dose

146,988

People Fully Vaccinated

0

Doses Received by a Vaccine Provider

472,100

Doses Administered

146,988

246 of 254
Counties with Vaccine Doses Administered

Last Updated
12/28/2020 12:44 PM

Summary | Vaccine Distribution | Vaccine Doses Administered | People Vaccinated | About the Data

TEXAS Health and Human Services | Texas Department of State Health Services

COVID-19 Vaccination in Texas

Select a Texas county below to view the number people who have received at least one dose of COVID-19 vaccine and those who have received the number of doses recommended by the CDC (People Fully Vaccinated).

Alternatively, click on a county on the map. Click the Revert button at the bottom of the screen to remove filters.

People Vaccinated with at least One Dose	People Fully Vaccinated
146,988	0

Search for a County

(All)

Texans Vaccinated by Age in Texas





Dashboard is updated daily by 4 p.m. CST with data as of 11:59 the previous night.
For inquiries about the data, email COVIDVaccineQs@dshs.texas.gov.

Second Dose Allocation

Pfizer Example – 21 days apart (Moderna would have an extra week since it is 28 days apart)

- Pfizer dose ones shipped on December 14th, the second doses will be allocated to providers on December 28th.
  - All emails moving forward will now designate first or second dose within the allocation notification.
- Providers will have until Friday morning on January 1st to accept their allocation in VAOS.
- Accepted allocations will be initiated for shipment on Friday afternoon of January 1st.
- According to the CDC, these vaccines should be delivered either January 4th or January 5th.

News from the Field

News from the Field

- Vaccine Receipt Issues
- Number of Doses per vial
- Adverse events and reporting
- v-safe

	moderna	Pfizer
Technology Platform	**mRNA**	
Indication	≥18 years	≥16 years
Dose	100 mcg (0.5mL) IM	30 mcg (0.3mL) IM
2-Dose Series	Day 0 & Day 28 ≤ 4-day grace period (e.g., day 24-28)	Day 0 & Day 21 ≤ 4-day grace period (e.g., day 17-21)
	2nd dose should be administered as close to the recommended interval as possible. However, there is no maximum interval between 1st and the 2nd dose.	
Interchangeability	• The two vaccines are not interchangeable with each other. • The safety and efficacy of a mixed-product series have not been evaluated. • Both doses of the series should be completed with the same product. • However, if two doses of different mRNA COVID-19 vaccine products are inadvertently administered, no additional doses of either product are recommended at this time.	
Coadministration with other vaccines	• The vaccine series should be administered alone, with a minimum interval of 14 days before or after administration with any other vaccines. • If mRNA COVID-19 vaccines are inadvertently administered within 14 days of another vaccine, doses do not need to be repeated for either vaccine.	

www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html

COVID-19 mRNA Vaccines

Warning - Management of Acute Allergic Reactions

- Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID-19 Vaccine.
- Monitor Moderna COVID-19 vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines.
  - All vaccine recipients be observed for 15 minutes after vaccination.
  - Person with a history of anaphylaxis, due to any cause, be observed for 30 minutes after vaccination.

https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxis-management.html

COVID-19 mRNA Vaccines Ingredients

www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html

TEXAS Health and Human Services

Texas Department of State Health Services

Description	Pfizer-BioNTech COVID-19 vaccine	Moderna COVID-19 vaccine
mRNA	Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2	Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2
Lipids	2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide	Polyethylene glycol (PEG) 2000 dimyristoyl glycerol (DMG)
	1,2-distearoyl-sn-glycero-3-phosphocholine	1,2-distearoyl-sn-glycero-3-phosphocholine
	Cholesterol	Cholesterol
	(4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)	SM-102 (Proprietary to Moderna)
Salts, sugars, buffers	Potassium chloride	Tromethamine
	Monobasic potassium phosphate	Tromethamine hydrochloride
	Sodium chloride	Acetic acid
	Dibasic sodium phosphate dihydrate	Sodium acetate
	Sucrose	Sucrose

COVID-19 mRNA Vaccines Triage Schema

www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html

Texas Department of State Health Services

	MAY PROCEED WITH VACCINATION	PRECAUTION TO VACCINATION	CONTRAINDICATION TO VACCINATION
CONDITIONS	**CONDITIONS** • Immunocompromising conditions • Pregnancy • Lactation **ACTIONS** • Additional information provided* • 15 minute observation period	**CONDITIONS** • Moderate/severe acute illness **ACTIONS** • Risk assessment • Potential deferral of vaccination • 15 minute observation period if vaccinated	**CONDITIONS** • None **ACTIONS** • N/A
ALLERGIES	**ALLERGIES** • History of food, pet, insect, venom, environmental, latex, or other allergies not related to vaccines or injectable therapies • History of allergy to oral medications (including the oral equivalent of an injectable medication) • Non-serious allergy to vaccines or other injectables (e.g., no anaphylaxis) • Family history of anaphylaxis • Any other history of anaphylaxis that is not related to a vaccine or injectable therapy **ACTIONS** • 30 minute observation period: Persons with a history of severe allergic reaction (e.g., anaphylaxis) due to any cause • 15 minute observation period: Persons with allergic reaction, but not anaphylaxis	**ALLERGIES** • History of severe allergic reaction (e.g., anaphylaxis) to another vaccine (not including mRNA COVID-19 vaccines†) • History of severe allergic reaction (e.g., anaphylaxis) to an injectable therapy **ACTIONS:** • Risk assessment • Potential deferral of vaccination • 30 minute observation period if vaccinated	**ALLERGIES** • History of severe allergic reaction (e.g., anaphylaxis) to any component of an mRNA COVID-19 vaccine† **ACTIONS** • Do not vaccinate

Moderna COVID-19 Vaccine
Mandatory Provider Requirements for Administration under EUA

- Provider must provide to the individual receiving the vaccine the “Fact Sheet for Recipients and Caregivers” prior to vaccination.
- Must report doses administered in ImmTrac2 within 24 hours post vaccination
  - **Report complete information including race/ethnicity**
- Provider must report the following to the Vaccine Adverse Event Reporting System (VAERS): https://vaers.hhs.gov/reportevent.html
  - Vaccine administration errors whether or not associated with an adverse event,
  - Serious adverse events* (irrespective of attribution to vaccination),
  - Cases of Multisystem Inflammatory Syndrome (MIS) in adults, and
  - Cases of COVID-19 that result in hospitalization or death.

v-safe | *your role as a provider*

- Give patients a **v-safe** information sheet at the time of vaccination
- Encourage them to enroll and fill out the surveys when prompted

https://vsafe.cdc.gov/

V-safe now available in Spanish
https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html

v-safe info poster

v-safe info sheets

Important Reminders

- Accept vaccine orders in VAOS.
- Print out Fact Sheet and V-safe documents to give to individuals getting vaccinated.
- Fill out the shot record cards in the ancillary kit supplies.
- Report **daily** all doses administered data to ImmTrac2.
  - **Report complete information including race/ethnicity**
- Vaccinate with **URGENCY.**

TEXAS Health and Human Services

Texas Department of State Health Services

Manufacturer COVID-19 Vaccine Training & Education Series

- Pfizer will be hosting a series of training sessions to review information and answer questions.
- Please click on the link below to join the sessions at the designated times. Each training below is the same content.

Date & Time	Password
Attendee Link December 28th 10:00 am est	MPu7pemXp79
Attendee Link December 29th 10:00 am est	mWZiCiWQ555
Attendee Link December 30th 10:00 am est	FXz38tdHBx2

TEXAS Health and Human Services

Texas Department of State Health Services

Resources

Website for Providers:
www.dshs.texas.gov/coronavirus/immunize/provider-information.aspx

FAQ for Providers
https://www.dshs.texas.gov/immunize/covid19/COVIDproviderfaq.pdf

DSHS COVID-19 Vaccine Provider hotline:
(877) 835-7750, 8 a.m. to 5 p.m., Monday - Friday
Email: COVID19VacEnroll@dshs.texas.gov.
COVID19VacMgmt@dshs.texas.gov

Website to enroll as a COVID-19 provider:
EnrollTexasIZ.dshs.texas.gov.

General Questions:
Email: COVIDvaccineQs@dshs.texas.gov

Texans Vaccinated for COVID-19 website

Pfizer Medical Information

Visit **PfizerMedicalInformation.com** or call **1-800-438-1985**.

ImmTrac2 support Email:
ImmTrac2@dshs.texas.gov

V-safe
https://vsafe.cdc.gov/
https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html

Vaccine Adverse Event Reporting System (VAERS):
https://vaers.hhs.gov/reportevent.html

Moderna (Pregnancy Registry & MedInfo):
medinfo@modernatx.com
1-866- MODERNA (1-866-663-3762)
www.modernatx.com/covid19vaccine-eua

CDC McKesson:
Pfizer #: 833-272-6634
Moderna #: 833-343-2703

Q & A

DISCLAIMER

The information presented today is based on CDC's recent guidance and MAY change.

December 29, 2020